Mer­ck KGaA snaps up Ger­man CD­MO in boost to mR­NA port­fo­lio — in­clud­ing for Covid-19

Once thought un­like­ly as a mech­a­nism of ac­tion in vac­cines, mR­NA-based shots have stormed out to a lead in the fight against Covid-19. But mR­NA’s po­ten­tial ef­fect isn’t lim­it­ed to just vac­cines, and now Ger­man drug­mak­er Mer­ck KGaA is look­ing to find out just how far it can take the tech­nol­o­gy.

The Darm­stadt, Ger­many based bio­phar­ma has ac­quired mR­NA CD­MO AmpTec in Ham­burg, say­ing it plans to strength­en its own ca­pac­i­ties to de­vel­op and man­u­fac­ture mR­NA for cus­tomers to use in “vac­cines, treat­ments and di­ag­nos­tics ap­plic­a­ble in Covid-19 and many oth­er dis­eases.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER